Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of
rituximab-lenalidomide in patients with relapsed/refractory MCL.